Page 149 - Binder2

Benefit of
Durable Explanation
Biologics
Without tolerization, there's less need to
Fewer dose increase dosage, shorten intervals, or add
escalations and immunosuppressants. These “patches”
adjunct raise costs and risks without providing
therapies
true solutions.
Preventing clinical relapse avoids urgent
care, hospitalizations, surgeries, missed
Fewer relapses workdays, and disease progression—
helping maintain stability and lower
system-wide costs.
Early failures in biologics create distrust
and more restrictive payer policies.
Less payer Durable options offer predictability,
friction
supporting value-based care and
improving payer-provider dynamics.
Durable biologics reduce the need for
Less clinician frequent switches and administrative
frustration battles, restoring clinician confidence
and easing burnout.
Reliable therapies foster patient trust,
Higher patient adherence, and proactive health
trust and management—positively impacting all
engagement
stakeholders.

Durability is not a soft metric.
It’s not a bonus feature.
It’s the economic backbone of a biologic that belongs in a
value-driven healthcare system.

147